Johnson & Johnson's most recent trend suggests a bearish bias. One trading opportunity on Johnson & Johnson is a Bear Call Spread using a strike $155.00 short call and a strike $160.00 long call offers a potential 22.85% return on risk over the next 14 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $155.00 by expiration. The full premium credit of $0.93 would be kept by the premium seller. The risk of $4.07 would be incurred if the stock rose above the $160.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Johnson & Johnson is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Johnson & Johnson is bearish.
The RSI indicator is at 61.96 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Johnson & Johnson
Healthcare ETFs to Gain on Progress in Coronavirus Vaccine
Wed, 29 Apr 2020 19:29:07 +0000
The healthcare space is heated up with players rushing to come up with a vaccine for COVID-19.
Catalent and Johnson & Johnson Sign Coronavirus Vaccine Manufacturing Deal
Wed, 29 Apr 2020 18:02:00 +0000
Catalent expects to be ready to manufacture the drug giant's lead COVID-19 vaccine by January.
Fisher Asset Management Cuts Pfizer, Johnson & Johnson
Wed, 29 Apr 2020 16:29:53 +0000
Firms' largest sales of 2020 1st quarter Continue reading…
Is Emergent BioSolutions the Next Hot Coronavirus Stock?
Wed, 29 Apr 2020 12:48:00 +0000
The company recently ended up grabbing quite a bit of investor attention thanks to a recently announced partnership with Johnson & Johnson (NYSE: JNJ) to help manufacture the latter's COVID-19 vaccine. Over the past month, the company has signed agreements with a number of other COVID-19 vaccine makers as well. Does all this make Emergent BioSolutions the next hot coronavirus stock, one you should keep on your watch list?
Is Fate Therapeutics a Buy?
Wed, 29 Apr 2020 11:11:00 +0000
The cell therapy pioneer has a promising early-stage pipeline and just landed a huge partner. What should investors make of this high-risk, high-reward stock?
Also on Market Tamer…
Follow Us on Facebook